Factors Associated with Survival in ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Titre :
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
Auteur(s) :
Jannin, Arnaud [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Giudici, Fabiola [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
de la Fouchardière, Christelle [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Al Ghuzlan, A. [Auteur]
Institut Gustave Roussy [IGR]
Wassermann, Johanna [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Chougnet, Cécile N. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Drui, Delphine D. [Auteur]
Institut du Thorax [Nantes]
Godbert, Yann [Auteur]
Institut Bergonié [Bordeaux]
Ilouz, Frédéric [Auteur]
CHU d'Angers [Département Urgences]
Bardet, Steṕhane [Auteur]
Radiothérapie [Centre François Baclesse]
Zanetta, Sylvie [Auteur]
Service de radiothérapie [Centre Georges-François Leclerc]
Roudaut, Nathalie [Auteur]
Hopital de Bohars - CHRU Brest [CHU - BREST ]
Batisse Lignier, Marie [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Groussin, Lionel [Auteur]
Hôpital Cochin [AP-HP]
Klein, Marc O. [Auteur]
Zerdoud, Slimane [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Lamartina, Livia [Auteur]
Institut Gustave Roussy [IGR]
Département d'imagerie médicale [Gustave Roussy]
Baudin, Éric [Auteur]
Institut Gustave Roussy [IGR]
Département d'imagerie médicale [Gustave Roussy]
Decaussin-Petrucci, Myriam [Auteur]
Centre pour l'innovation en cancérologie de Lyon [CICLY]
Research on Healthcare Performance [RESHAPE - Inserm U1290 - UCBL1]
Leteurtre, Emmanuelle A. [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Borson Chazot, Françoise [Auteur]
Centre pour l'innovation en cancérologie de Lyon [CICLY]
Hospices Civils de Lyon [HCL]
Do Cao, Christine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Borget, Isabelle [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Institut Gustave Roussy [IGR]
Hadoux, Julien [Auteur]
Groupe Hospitalier Paul Guiraud [Villejuif] [GHPG]
Département d'imagerie médicale [Gustave Roussy]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Giudici, Fabiola [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
de la Fouchardière, Christelle [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Al Ghuzlan, A. [Auteur]
Institut Gustave Roussy [IGR]
Wassermann, Johanna [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Chougnet, Cécile N. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Drui, Delphine D. [Auteur]
Institut du Thorax [Nantes]
Godbert, Yann [Auteur]
Institut Bergonié [Bordeaux]
Ilouz, Frédéric [Auteur]
CHU d'Angers [Département Urgences]
Bardet, Steṕhane [Auteur]
Radiothérapie [Centre François Baclesse]
Zanetta, Sylvie [Auteur]
Service de radiothérapie [Centre Georges-François Leclerc]
Roudaut, Nathalie [Auteur]
Hopital de Bohars - CHRU Brest [CHU - BREST ]
Batisse Lignier, Marie [Auteur]
Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP]
Groussin, Lionel [Auteur]
Hôpital Cochin [AP-HP]
Klein, Marc O. [Auteur]
Zerdoud, Slimane [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Lamartina, Livia [Auteur]
Institut Gustave Roussy [IGR]
Département d'imagerie médicale [Gustave Roussy]
Baudin, Éric [Auteur]
Institut Gustave Roussy [IGR]
Département d'imagerie médicale [Gustave Roussy]
Decaussin-Petrucci, Myriam [Auteur]
Centre pour l'innovation en cancérologie de Lyon [CICLY]
Research on Healthcare Performance [RESHAPE - Inserm U1290 - UCBL1]
Leteurtre, Emmanuelle A. [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Borson Chazot, Françoise [Auteur]
Centre pour l'innovation en cancérologie de Lyon [CICLY]
Hospices Civils de Lyon [HCL]
Do Cao, Christine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Borget, Isabelle [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Institut Gustave Roussy [IGR]
Hadoux, Julien [Auteur]
Groupe Hospitalier Paul Guiraud [Villejuif] [GHPG]
Département d'imagerie médicale [Gustave Roussy]
Titre de la revue :
Thyroid
Pagination :
1190-1200
Éditeur :
Mary Ann Liebert
Date de publication :
2023-10-01
ISSN :
1050-7256
Mot(s)-clé(s) en anglais :
anaplastic thyroid carcinoma
neutrophil-to-lymphocyte ratio
overall survival
prognosis
targeted therapy
neutrophil-to-lymphocyte ratio
overall survival
prognosis
targeted therapy
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated ...
Lire la suite >Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France. Methods: In this multicenter, retrospective cohort study, all patients with ATC diagnosed between 2010 and 2020 were identified from the national database of the French ENDOCAN-TUTHYREF network. Factors associated with OS were examined in multivariable analyses using Cox proportional hazards models. Results: The study included 360 patients. Of these, 220 (61%) were female and the median age was 72 years (interquartile range: 62-80). The percentages of patients with pure and mixed (synchronously-transformed) ATC (p-ATC and st-ATC) were 62.5% and 26.7%, respectively. The median OS was 6.8 months [confidence interval, CI: 5.5-8.1]: not reached for stage IVa, 11.4 months [8.2-17.8] for IVb, and 4.6 months [3.5-5.7] for IVc. Surgery, radiation therapy to the neck, chemotherapy, and best supportive care were administered to 69 (19.2%), 214 (59.4%), 254 (70.6%), and 66 (18.3%) patients, respectively. In a multivariable analysis, including stage IVb-IVc patients, significantly higher OS was observed in patients with Eastern Cooperative Oncology Group performance-status of 0-1 (hazard ratio [HR], 0.6; [CI, 0.4-0.9], p < 0.02), stage IVb [HR, 0.5; CI, 0.4-0.8, p < 0.001], and multimodal treatment (surgery and chemoradiotherapy) [HR, 0.07; CI, 0.04-0.1, p < 0.001]. Variables associated with significantly worse OS included: p-ATC (vs. st-ATC) [HR, 1.83; CI, 1.33-2.51, p = 0.001] and a neutrophil-to-lymphocyte ratio (NLR) >5.05 [HR, 2.05, CI, 1.39-3.05, p < 0.001]. Conclusions: Factors independently associated with improved OS in ATC included: European Cooperative Oncology Group performance status, disease stage, multimodality treatment, synchronously transformed ATC, and lower NLR. Long-term OS was observed in selected patients with ATC who underwent multimodal treatmenLire moins >
Lire la suite >Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France. Methods: In this multicenter, retrospective cohort study, all patients with ATC diagnosed between 2010 and 2020 were identified from the national database of the French ENDOCAN-TUTHYREF network. Factors associated with OS were examined in multivariable analyses using Cox proportional hazards models. Results: The study included 360 patients. Of these, 220 (61%) were female and the median age was 72 years (interquartile range: 62-80). The percentages of patients with pure and mixed (synchronously-transformed) ATC (p-ATC and st-ATC) were 62.5% and 26.7%, respectively. The median OS was 6.8 months [confidence interval, CI: 5.5-8.1]: not reached for stage IVa, 11.4 months [8.2-17.8] for IVb, and 4.6 months [3.5-5.7] for IVc. Surgery, radiation therapy to the neck, chemotherapy, and best supportive care were administered to 69 (19.2%), 214 (59.4%), 254 (70.6%), and 66 (18.3%) patients, respectively. In a multivariable analysis, including stage IVb-IVc patients, significantly higher OS was observed in patients with Eastern Cooperative Oncology Group performance-status of 0-1 (hazard ratio [HR], 0.6; [CI, 0.4-0.9], p < 0.02), stage IVb [HR, 0.5; CI, 0.4-0.8, p < 0.001], and multimodal treatment (surgery and chemoradiotherapy) [HR, 0.07; CI, 0.04-0.1, p < 0.001]. Variables associated with significantly worse OS included: p-ATC (vs. st-ATC) [HR, 1.83; CI, 1.33-2.51, p = 0.001] and a neutrophil-to-lymphocyte ratio (NLR) >5.05 [HR, 2.05, CI, 1.39-3.05, p < 0.001]. Conclusions: Factors independently associated with improved OS in ATC included: European Cooperative Oncology Group performance status, disease stage, multimodality treatment, synchronously transformed ATC, and lower NLR. Long-term OS was observed in selected patients with ATC who underwent multimodal treatmenLire moins >
Langue :
Anglais
Vulgarisation :
Non
Collections :
Source :